Evidence review

VIP for Sciatica: Repair Layers and the Evidence on VIP, BPC-157, TB-500, ARA-290

#peptide#matrix
bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects (paste without context)

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `vip-sciatica`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/vip-sciatica

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/vip-sciatica/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Paste-ready package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/vip-sciatica/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/vip-sciatica/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/vip-sciatica/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down if you have Sciatica

  1. Sciatica is nerve pain along the sciatic nerve — often from disc herniation or stenosis compressing a root.
  2. The nerve is signaling damage/compression; suppressing pain does not uncompress the nerve.

Why VIP might help you

  1. You have Sciatica — breakdown is outpacing repair.
  2. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.
  3. This article centers VIP; see other sections for bpc-157, tb-500, ara-290 — different layers, same condition.

Why BPC-157 might help you

  1. You have Sciatica — breakdown is outpacing repair.
  2. What keeps failing: Poor blood supply at injury, weak collagen organization, slow tissue turnover.
  3. What BPC-157 is studied to do: Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.
  4. Therefore for you: If that layer is part of your problem, BPC-157 is discussed because it targets repair (structure / tissue) — not because it masks pain.

Why TB-500 might help you

  1. You have Sciatica — breakdown is outpacing repair.
  2. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.
  3. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.
  4. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.

Why ARA-290 might help you

  1. You have Sciatica — breakdown is outpacing repair.
  2. What keeps failing: Nerve compression, small-fiber loss, neuropathic pain signaling without tissue repair.
  3. What ARA-290 is studied to do: Studied for nerve repair and small-fiber regeneration in neuropathy models.
  4. Therefore for you: If that layer is part of your problem, ARA-290 is discussed because it targets repair (nerve / innervation) — not because it masks pain.

How these fit together

Each compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.

  • VIP → immune / autonomic
  • BPC-157 → structure / tissue
  • TB-500 → inflammation clearance / repair-cell migration
  • ARA-290 → nerve / innervation

Primary focus of this slug: VIP. Others are in scope because the same condition breaks down on multiple layers.

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 6
  • Claims tagged human evidence: 2
  • Claims tagged preclinical (animal/lab): 4
  • Claims tagged anecdotal: 0
  • Reddit posts catalogued: 0
  • X posts catalogued: 0
  • Other anecdote sources (YouTube, Instagram, etc.): 0
  • Total sources in chain: 7

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.55 / 1.00 — moderate — human claims present in ledger

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Distinct VIP and PACAP Functions in the Distal Nerve Stump Following Peripheral Nerve Injury (source s12)

Mouse sciatic nerve transection study showing VIP receptor upregulation in Schwann cells and macrophages; VIP effects on cytokine balance and remyelination in explants.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

The effects of vasoactive intestinal peptide in the rat model of experimental autoimmune neuritis (source s17)

Rat EAN model demonstrating VIP's impact on sciatic nerve inflammation and function.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats (source s1)

Rat studies on BPC-157 after nerve and spinal injury showing recovery metrics.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats (source s6)

Detailed rat spinal cord compression model with BPC-157 outcomes.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

Targeting the innate repair receptor to treat neuropathy (source s33)

Review summarizing human ARA290 trials in neuropathy populations.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Targeting the innate repair receptor to treat neuropathy (source s34)

Human clinical outcomes for ARA290 in sarcoidosis and diabetic neuropathy.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Peptide components (collapsible embeds)

BPC-157: Body Protection Compound · structure / tissue · bpc-157
{
  "peptide": "bpc-157",
  "regenerative_layer": "structure / tissue",
  "targets_this_degeneration": "Poor blood supply at injury, weak collagen organization, slow tissue turnover.",
  "proposed_regeneration": "Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.",
  "evidence_in_ledger": {
    "human_claims": 24,
    "preclinical_claims": 4,
    "anecdote_claims": 67,
    "studies_catalogued": 35
  },
  "confidence_0_to_1": 0.95,
  "confidence_label": "moderate (human data present)",
  "full_article": "https://miscsubjects.com/a/bpc-157"
}

Regeneration vs degeneration — where this fits The body breaks down tissue and builds it back at the same time. When breakdown stays ahead of repair, pain or weakness stays. Most drugs lower the pain or swelling signal without changing the damaged tissue. BPC-157 is studied for a different path: it is examined for step…

Full bpc-157 article →
TB-500: Thymosin Beta-4 · inflammation clearance / repair-cell migration · tb-500
{
  "peptide": "tb-500",
  "regenerative_layer": "inflammation clearance / repair-cell migration",
  "targets_this_degeneration": "Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.",
  "proposed_regeneration": "Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.",
  "evidence_in_ledger": {
    "human_claims": 14,
    "preclinical_claims": 4,
    "anecdote_claims": 74,
    "studies_catalogued": 25
  },
  "confidence_0_to_1": 0.95,
  "confidence_label": "moderate (human data present)",
  "full_article": "https://miscsubjects.com/a/tb-500"
}

Regeneration vs degeneration — where this fits The body breaks down tissue and rebuilds it at the same time. When breakdown stays ahead of repair, injury or disease persists. Most drugs block signals such as pain or swelling without rebuilding the tissue that created the signal. TB-500 is studied for repair pathways: i…

Full tb-500 article →
ARA-290: Nerve Repair Peptide · nerve / innervation · ara-290
{
  "peptide": "ara-290",
  "regenerative_layer": "nerve / innervation",
  "targets_this_degeneration": "Nerve compression, small-fiber loss, neuropathic pain signaling without tissue repair.",
  "proposed_regeneration": "Studied for nerve repair and small-fiber regeneration in neuropathy models.",
  "evidence_in_ledger": {
    "human_claims": 13,
    "preclinical_claims": 1,
    "anecdote_claims": 45,
    "studies_catalogued": 21
  },
  "confidence_0_to_1": 0.95,
  "confidence_label": "moderate (human data present)",
  "full_article": "https://miscsubjects.com/a/ara-290"
}

Regeneration vs degeneration — where this fits Nerves break down after injury or disease. Small fiber neuropathy is one case where breakdown outruns repair. Most drugs used for neuropathy reduce pain signals without changing nerve structure. ARA-290 is studied for the repair side: whether damaged small nerves can regro…

Full ara-290 article →

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Sciatica · condition map

Evidence map

Hover a node — its path lights up. Click to open the article.

Full map →
JumpVIP for Statin-Associated Cognitive Effects: Evidence Review · 2 humanVIP Peptide for Chemotherapy Contexts: Evidence on Immune and Autonomi… · 2 humanVIP for Chemotherapy-Induced Neuropathy: A Data-First Evidence Review · 2 humanVIP for Diabetic Neuropathy: Evidence-Graded Overview · 2 human
Evidence · 7 sources · swipe →chain 31cd5b3c99d6 · verify chain · provenance
1 / 7
Evidence ledger 6 · tier-ranked · API
human
No published human clinical trials exist for VIP, BPC-157, or TB-500 in sciatica or disc herniation.
preclinical
VIP expression increases after peripheral nerve injury in rat and mouse sciatic nerve models and supports remyelination and anti-inflammatory cytokine shifts in the distal stump.
sources: s12
humanlow confidence
In human Phase II trials, ARA-290 improved neuropathic symptoms and quality of life in patients with small fiber neuropathy from sarcoidosis or type 2 diabetes; some showed corneal nerve fiber regrowth.
sources: s33, s34
preclinicallow confidence
In a rat experimental autoimmune neuritis model, VIP treatment led to functional improvement and reduced inflammation in the sciatic nerve.
sources: s17
preclinicallow confidence
BPC-157 improved functional recovery and rescued somatosensory neurons after sciatic nerve transection and spinal cord compression in rat models.
sources: s1, s6
1 more ranked claim
preclinical0.22low confidence
Long-term thymosin beta-4 (TB-500) administration in diabetic mice prevented neuropathy progression and restored sciatic nerve motor and sensory function.
grok/grok-4.3
Animal evidence tying TB-500 to sciatic nerve functional recovery.
sources: s29
Model swipes · 1 from 1 model · swipe →verify
1 / 1
grok/grok-4.3writer
redraft2026-06-29 22:20
VIP for Sciatica: Repair Layers and the Evidence on VIP, BPC-157, TB-500, ARA-290 · 6 claims · 7 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: Write a data-first, evidence-graded article: Vip for Sciatica
Slug: vip-sciatica
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"multi_stack","condition":"Sciatica","condition_key":"sciatica","primary_peptide":"vip","peptides_in_scope":[{"id":"vip","name":"VIP"},{"id":"bpc-157","name":"BPC-157"},{"id":"tb-500","name":"TB-500"},{"id":"ara-290","name":"ARA-290"}],"drugs_in_scope":[],"weight_sensitive":true,"stimulant_context":fa
it output
```json
{
  "slug": "vip-sciatica",
  "title": "VIP for Sciatica: Repair Layers and the Evidence on VIP, BPC-157, TB-500, ARA-290",
  "body": "## What's breaking down if you have Sciatica\n\nSciatica is nerve pain along the sciatic nerve, often from disc herniation or stenosis compressing a root. The nerve signals damage or compression. Suppressing pain does not uncompress the nerve or restore tissue.\n\nBreakdown outruns repair at multiple layers: immune and autonomic signaling, structural tissue integrity, inflammation clearance and cell migration, and direct nerve fiber health. Peptides in scope are studied for specific repair pathways rather than symptom masking.\n\n## Why VIP might help you\n\n1. You have sciatica — breakdown is outpacing repair.\n2. Therefore for you: If the immune and autonomic layer is part of your problem, VIP is discussed because it targets repair pathways in nerve tissue and inflammation regulation — not because it masks pain.\n3. This article centers VIP; see other sections for BPC-157, TB-500, and ARA-290 — different layers, same condition.\n\n## Why BPC-157 might help you\n\n1. You have sciatica — breakdown is outpacing repair.\n2. What keeps failing: Poor blood supply at injury sites, weak collagen organization, slow tissue turnover.\n3. What BPC-157 is studied to do: Studied for growing new blood vessels so repair material reaches damaged tissue
e4bf2ae94a019afe

Related research

Sciatica · condition map

Open evidence map →
BPC-157: Body Protection Compoundpeptide in this stackbpc-157TB-500: Thymosin Beta-4peptide in this stacktb-500ARA-290: Nerve Repair Peptidepeptide in this stackara-290VipvipVIP for Benzodiazepine Withdrawal: Evidence Reviewvip-benzo-withdrawalVIP and Benzodiazepines: Immune and Autonomic Pathways in a Suppressio…vip-benzodiazepinesVIP for Statin-Associated Cognitive Effects: Evidence Reviewvip-brain-fogVIP for Carpal Tunnel Syndrome: A Data-First Evidence Reviewvip-carpal-tunnelVIP Peptide for Chemotherapy Contexts: Evidence on Immune and Autonomi…vip-chemoVIP for Chemotherapy-Induced Neuropathy: A Data-First Evidence Reviewvip-chemo-neuropathy
Ask this article · 8 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "No published human clinical trials exist for VIP, BPC-157, or TB-500 in sciatica or disc herniation."?
ask vip-sciatica claim c6 · paste includes §SELF
What does the ledger say about this (preclinical tier): "VIP expression increases after peripheral nerve injury in rat and mouse sciatic nerve models and supports remyelination and anti-inflammator…"?
ask vip-sciatica claim c1 · paste includes §SELF
What does the ledger say about this (human tier): "In human Phase II trials, ARA-290 improved neuropathic symptoms and quality of life in patients with small fiber neuropathy from sarcoidosis…"?
ask vip-sciatica claim c5 · paste includes §SELF
What does the ledger say about this (preclinical tier): "In a rat experimental autoimmune neuritis model, VIP treatment led to functional improvement and reduced inflammation in the sciatic nerve."?
ask vip-sciatica claim c2 · paste includes §SELF
What does the ledger say about this (preclinical tier): "BPC-157 improved functional recovery and rescued somatosensory neurons after sciatic nerve transection and spinal cord compression in rat mo…"?
ask vip-sciatica claim c3 · paste includes §SELF
What does the ledger say about this (preclinical tier): "Long-term thymosin beta-4 (TB-500) administration in diabetic mice prevented neuropathy progression and restored sciatic nerve motor and sen…"?
ask vip-sciatica claim c4 · paste includes §SELF
For my medical situation, what can you answer from your catalogue about VIP for Sciatica: Repair Layers and the Evidence on VIP, BPC-157, TB-500, ARA-290 — and what would you need me to tell you first?
ask vip-sciatica condition gaps · paste includes §SELF
What good and bad outcomes are documented for VIP for Sciatica: Repair Layers and the Evidence on VIP, BPC-157, TB-500, ARA-290 (studies vs anecdotes)?
ask vip-sciatica good bad experiences · paste includes §SELF
vip-sciatica · posted 2026-06-29 · updated 2026-06-29 · 1 prior revision · grok/grok-4.3
Ledger API & provenance
Provenance · 1 model pass · 26188 tokens · $0 · 1 model
chain head 54674d7f9f294527
write grok/grok-4.3 · 2026-06-29 22:20 · 26188 tok · 54674d7f9f29
verify chain →
Live ledger · 6 payloads · 1 turn
recent activity · inspect
webhook_in blooio · 2026-06-29 22:20
PROTOCOL_RUN dispatch · 2026-06-29 22:20 · t_0r2fd5en
PROTOCOL_RUN dispatch · 2026-06-29 22:20 · t_0r2fd5en
webhook_in blooio · 2026-06-29 22:20
webhook_in blooio · 2026-06-29 22:20
webhook_in blooio · 2026-06-29 22:20
view full ledger & cards →
REST + ledger
read GET /api/articles/vip-sciatica · GET /api/articles/vip-sciatica?format=post (the editable body)
create/replace POST /api/articles/vip-sciatica · PUT /api/articles/vip-sciatica (replace, keeps revision) · PATCH /api/articles/vip-sciatica (merge)
delete DELETE /api/articles/vip-sciatica
writes need header x-terminal-key
ledger provenance · sources · contributions · revisions · live ledger & cards
LLM bundle GET /api/articles/vip-sciatica/bundle?format=markdown — body + claims + sources + provenance + manifest
voxel graph GET /api/articles/vip-sciatica/voxels · constitution · ontology
post claim POST /api/protocol/claim · iMessage claim vip-sciatica|tier|assertion
system map GET /api/articles/system-map?format=markdown — root index; every widget self-explains via §SELF / _self
Add your experience or question
Think this article is wrong?
Call bullshit on CharlieOS →